Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 8/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7678043 | 0.76 | MAPT (0.59) | NFKB1ALDH1A1MAPTCRHR1 | |
| SCHEMBL14347187 | 0.75 | RXFP1 (0.39) | ALDH1A1MAPTCRHR1SMN1; SMN2 | |
| SCHEMBL7678044 | 0.71 | MEN1 (0.40) | ALDH1A1MAPTIGF1RCRHR1SMN1; SMN2 | |
| SCHEMBL5496929 | 0.70 | CRHR1 (0.40) | MAPTCRHR1SMN1; SMN2 | |
| SCHEMBL7680556 | 0.69 | MAPT (0.43) | ALDH1A1MAPTIGF1RCRHR1SMN1; SMN2 | |
| SCHEMBL7687760 | 0.69 | NPC1 (0.39) | NFKB1ALDH1A1MAPTIGF1RCRHR1 | |
| SCHEMBL5492382 | 0.68 | CRHR1 (0.36) | CRHR1 | |
| SCHEMBL6094653 | 0.68 | WDR5 (0.40) | CRHR1 | |
| SCHEMBL7683030 | 0.67 | ALDH1A1 (0.41) | ALDH1A1MAPTCRHR1 | |
| SCHEMBL5434555 | 0.67 | MAPT (0.46) | ALDH1A1MAPTCRHR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270588-A1 | Pyrrolopyrimidine Derivatives | TAISHO PHARMACEUTICAL CO., LTD. | 2007-11-22 | — | — | US | disclosed |
| US-20070270588-A1 | Pyrrolopyrimidine Derivatives | TAISHO PHARMACEUTICAL CO., LTD. | 2007-11-22 | — | — | US | disclosed |
| US-20070270588-A1 | Pyrrolopyrimidine Derivatives | TAISHO PHARMACEUTICAL CO., LTD. | 2007-11-22 | — | — | US | disclosed |
| EP-1725562-A1 | PYRROLOPYRIMIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085253-A1 | PYRROLOPYRIMIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270588-A1 | Pyrrolopyrimidine Derivatives | HRH2, ALPI, HRH1 | NFKB1 1942/4885ALDH1A1 3031/4885MAPT 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.